rs33996649 — PTPN22 R263Q

PTPN22 R263Q — The Protective Brake on Immune Hyperactivation

The PTPN22 gene encodes lymphoid tyrosine phosphatase (LYP), a master brake on T-cell and B-cell activation. While the well-known R620W variant (rs2476601) increases autoimmune risk by disrupting regulatory interactions, the R263Q variant works through an entirely different mechanism — it reduces the catalytic phosphatase activity¹¹ reduces the catalytic phosphatase activity
R263Q is a loss-of-function missense substitution in the PTPN22 catalytic domain, reducing enzymatic dephosphorylation of key T-cell signaling proteins of the enzyme itself. Carriers of the T allele (representing the Q263 amino acid) have a somewhat weaker LYP phosphatase, which paradoxically helps maintain better immune tolerance and reduces risk for several autoimmune conditions.

The Mechanism

Position 263 lies within the catalytic domain of LYP, where arginine-263 forms a stabilizing contact with glutamine-34. The R263Q substitution — arginine to glutamine — disrupts this contact, displacing the α2′ helix²² displacing the α2′ helix
Crystal structure analysis showed displacement of the α2′ helix in R263Q, resulting in an altered substrate-binding cleft with open WPD-loop configuration versus the half-closed wild-type conformation and reconfiguring the substrate-binding pocket. The resulting protein retains its basic fold but has reduced ability to dephosphorylate its physiological substrates — primarily the Src-family kinase Lck, ZAP-70, and the TCR-zeta chain. With a less active phosphatase, T-cell receptor signaling proceeds with somewhat less suppression, supporting more robust responses to antigens including self-antigens at tolerance-induction checkpoints.

Crucially, this mechanism is independent of and structurally distinct from R620W. Where R620W sits in the C-terminal proline-rich P1 motif and disrupts CSK binding, R263Q sits directly in the catalytic domain and impairs enzymatic function. Genetic studies confirm complete independence³³ Genetic studies confirm complete independence
The R263Q and R620W polymorphisms show no linkage disequilibrium and their autoimmune associations are statistically independent. Notably, all non-human species examined encode glutamine at position 263 — suggesting the ancestral Q263 form is the evolutionarily conserved variant, and the common R263 (C allele) represents the derived human-specific change.

The Evidence

The protective effect of Q263 (T allele) has been replicated across multiple disease contexts and populations. The founding study by Orrú et al. 2009⁴⁴ Orrú et al. 2009
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet, 2009 demonstrated SLE protection across four cohorts (Spain, Italy, Argentina, US) totaling 2,093 patients and 2,348 controls, with a pooled OR of 0.63 (95% CI 0.47–0.84, p=0.0017). The Q263 allele frequency was approximately 1.7–3.4% across cohorts, consistent with a rare but functionally important variant.

For rheumatoid arthritis, Rodríguez-Rodríguez et al. 2011⁵⁵ Rodríguez-Rodríguez et al. 2011
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples. Arthritis Rheum, 2011 studied 10,971 participants across six European countries and showed the T allele associated with reduced RA risk (OR 0.80, 95% CI 0.67–0.96, p=0.016). Additive analysis confirmed that carrying fewer T alleles at R263Q compounded RA risk: individuals homozygous for the common C allele at R263Q and the risk allele at R620W faced the highest combined risk.

For inflammatory bowel disease, Diaz-Gallo et al. 2011⁶⁶ Diaz-Gallo et al. 2011
Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis, 2011 showed a striking disease-specific pattern in 6,691 participants: R263Q protected against ulcerative colitis (meta-analysis OR 0.69, 95% CI 0.51–0.93) but showed no association with Crohn's disease. This dissociation — combined with R620W's opposite pattern (associated with Crohn's but not UC) — underscores that the two PTPN22 coding variants affect distinct immunological pathways despite sharing the same gene.

Notably, R263Q does not appear to protect against type 1 diabetes, Graves' disease, systemic sclerosis, or uveitis — conditions where R620W has well-documented associations. This specificity may reflect differences in the immune cell types and signaling thresholds relevant to each disease.

Practical Implications

Carrying one or two copies of the T allele (CT or TT genotype) is associated with modestly lower baseline risk for SLE, RA, and ulcerative colitis. This is a meaningful genetic buffer, particularly for individuals with family history of these conditions. The protective effect is most clearly documented in European-ancestry populations; the variant is essentially absent in East Asian and African populations, so the evidence base largely applies to Europeans and Hispanics.

Reduced genetic risk does not eliminate risk entirely — autoimmune diseases are polygenic and heavily influenced by environmental triggers, HLA alleles, hormonal factors, and microbiome composition. The T allele provides a partial protective signal, not immunity.

Interactions

R263Q and R620W (rs2476601) are the two characterized functional coding variants in PTPN22, and their effects are additive. The combination of CC at R263Q (no Q263 protection) with the risk genotype at R620W yields the highest autoimmune risk. Rodríguez-Rodríguez et al. 2011⁷⁷ Rodríguez-Rodríguez et al. 2011
Additive PTPN22 risk allele analysis: 2 risk alleles OR 1.28, 3 risk alleles OR 2.01, 4 risk alleles OR 3.55 quantified this: carrying four risk alleles (CC at R263Q + TT at R620W) raised RA risk 3.5-fold compared to baseline. Conversely, carrying the T allele at R263Q may partially offset R620W risk.

The mechanistic independence of the two variants — one in the catalytic domain, one in the regulatory P1 motif — means they affect different aspects of LYP function. Neither variant is in linkage disequilibrium with the other, so each must be assessed individually.